在转甲状腺素蛋白心脏淀粉样变患者中帕替拉韦的心血管安全性：一项荟萃分析。 - Suppr

Suppr

超能文献

Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis.

作者信息

Jaiswal Vikash, Kalra Kriti, Deb Novonil, Mattumpuram Jishanth

机构信息

Department of Medicine, AMA School of Medicine, Makati, Philippines.

Department of Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.

出版信息

Am J Cardiovasc Drugs. 2025 Jan;25(1):125-127. doi: 10.1007/s40256-024-00699-5. Epub 2024 Nov 22.

DOI:10.1007/s40256-024-00699-5

PMID:39578331

Abstract

摘要

相似文献

Cardiovascular Safety of Patisiran Among Transthyretin Cardiac Amyloidosis: A Meta-analysis.在转甲状腺素蛋白心脏淀粉样变患者中帕替拉韦的心血管安全性：一项荟萃分析。

Am J Cardiovasc Drugs. 2025 Jan;25(1):125-127. doi: 10.1007/s40256-024-00699-5. Epub 2024 Nov 22.

Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.帕替沙兰用于治疗转甲状腺素蛋白介导的淀粉样变心肌病

Heart Int. 2023 Jun 8;17(1):27-35. doi: 10.17925/HI.2023.17.1.27. eCollection 2023.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者用 patisiran 的长期安全性和疗效：一项开放标签扩展研究的 12 个月结果。

Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.在遗传性转甲状腺素蛋白介导的（hATTR）淀粉样变性患者的 3 期 APOLLO 试验中，帕替沙那的药代动力学、药效学和暴露-反应分析。

J Clin Pharmacol. 2020 Jan;60(1):37-49. doi: 10.1002/jcph.1480. Epub 2019 Jul 19.

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.Patisiran 治疗转甲状腺素蛋白心脏淀粉样变心肌病患者。

N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757.

Treatment of transthyretin His88Arg amyloidosis with RNA interference therapy: A case report.RNA干扰疗法治疗转甲状腺素蛋白His88Arg淀粉样变性：一例报告

J Cardiol Cases. 2022 Jan 20;25(6):363-366. doi: 10.1016/j.jccase.2021.12.012. eCollection 2022 Jun.

Left Ventricular Deformation and Myocardial Work Parameters in Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran: A Single-Center Study.帕替沙兰治疗遗传性转甲状腺素蛋白淀粉样变性患者的左心室变形和心肌工作参数：一项单中心研究

J Clin Med. 2024 Aug 20;13(16):4914. doi: 10.3390/jcm13164914.

Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis.伴有转甲状腺素蛋白稳定剂的 patisiran 治疗遗传性转甲状腺素蛋白介导的淀粉样变性病患者的经验。

Neurodegener Dis Manag. 2020 Oct;10(5):289-300. doi: 10.2217/nmt-2020-0020. Epub 2020 Jun 10.

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.Patisiran，一种 RNA 干扰治疗药物，与遗传性转甲状腺素淀粉样变心肌病的左心室局部心肌应变的相关性：APOLLO 研究。

JAMA Cardiol. 2019 May 1;4(5):466-472. doi: 10.1001/jamacardio.2019.0849.

Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study.载脂蛋白研究的压力-容积分析：帕替沙那对遗传性转甲状腺素蛋白介导的淀粉样变性患者每搏量的影响。

Eur J Heart Fail. 2023 May;25(5):727-736. doi: 10.1002/ejhf.2783. Epub 2023 Feb 6.

引用本文的文献

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials.钠-葡萄糖协同转运蛋白2抑制剂与心律失常：38项随机对照试验的荟萃分析

JACC Adv. 2025 Mar;4(3):101615. doi: 10.1016/j.jacadv.2025.101615. Epub 2025 Feb 22.

本文引用的文献

Clinical and Cardiovascular Magnetic Resonance Imaging Features of Cardiac Amyloidosis.心脏淀粉样变性的临床及心血管磁共振成像特征

Rev Cardiovasc Med. 2023 Oct 16;24(10):291. doi: 10.31083/j.rcm2410291. eCollection 2023 Oct.

Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis.植入式心脏复律除颤器用于缺血性和非缺血性心肌病患者的一级预防：一项荟萃分析。

Curr Probl Cardiol. 2024 Feb;49(2):102198. doi: 10.1016/j.cpcardiol.2023.102198. Epub 2023 Nov 11.

Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.Patisiran 治疗转甲状腺素蛋白心脏淀粉样变心肌病患者。

N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757.

ATTR Amyloidosis: Current and Emerging Management Strategies: State-of-the-Art Review.转甲状腺素蛋白淀粉样变性：当前及新出现的管理策略：最新综述

JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct.

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.帕替拉韦，一种用于治疗遗传性转甲状腺素蛋白介导的淀粉样变性的RNA干扰疗法。

Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27.

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.用于遗传性转甲状腺素蛋白淀粉样变性的 RNAi 治疗药物 Patisiran

N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.

Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.心脏淀粉样变性：病理生理学、诊断和治疗的最新进展。

Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验